Brookfield places a $3.3bn bid to acquire Australia’s Healthscope

By Catherine Sturman
Australian healthcare provider Healthscope has revealed that it has received a new $3.3bn proposal from Canadian investment company Brookfield Asset Man...

Australian healthcare provider Healthscope has revealed that it has received a new $3.3bn proposal from Canadian investment company Brookfield Asset Management, surpassing a local buyout proposal.

A potential deal with Healthscope and Brookfield would make the acquisition one of the largest healthcare takeovers by a Canadian company to date.

Shares have risen to a two-year high at 4.9% and will now see the start of a potential bidding war between BGH Capital and AustralianSuper, who partnered last month to prepare a joint proposal of $3.1bn in a new consortium.

“All members of the consortium will reject, vote against or not accept any proposal for the acquisition of Healthscope shares that may be put forward by any other party,” the duo have stated in a joint statement.

See also

At present, AustralianSuper has over 15% stake in Healthscope, and has previously stated that it would disregard any offers, even if they are larger than previous offers.

With this in mind, it will be interesting to see whether Brookfield will attempt to split the consortium by speaking directly with Healthscope’s board to pave the way for a potential deal. The company has stated that its offer will only be valid if AustralianSuper is prevented from voting against the move.

Interestingly, the news follows on from Northwest Healthcare’s recent 10% stake in Healthscope, which it acquired for $312mn.

Brookfield is presently being represented by Bank of America Merrill Lynch, whilst Healthscope has appointed UBS in its bid.

Share

Featured Articles

McKinsey Health Institute: Focus on Healthcare Insights Body

McKinsey Health Institute generates healthcare insights that McKinsey's consulting teams can draw upon for the benefit of its customers

AstraZeneca & Celonis Map out Digital Transformation

AstraZeneca's Raaj Joshi discusses sustainable innovation in pharmaceutical manufacturing & the company's digital transformation, undertaken with Celonis

Google DeepMind's AlphaFold 3 'is Drug Discovery Boost'

Google DeepMind's AlphaFold 3 is an AI model that can predict the structures and interactions of molecules and will help scientists unlock new medicines

UnitedHealth CEO Admits Hack hit Third of US Citizens' Data

Digital Healthcare

Why Sanofi Leads the way on Healthcare Sustainability

Sustainability

Philips Q1 Results hit by $1.1bn Respironics Settlement

Medical Devices & Pharma